Jubilant Pharmova Announces Unaudited Financial Results for Quarter Ended June 30, 2026
Jubilant Pharmova Limited has reported its unaudited financial results for the quarter ended June 30, 2026, covering both standalone and consolidated performance. The Company’s Board of Directors approved these results at a meeting held on August 10, 2026.The consolidated results reflect significant revenue generation across various operational segments for the Group.
Consolidated Performance Overview
For the quarter ending June 30, 2026, the consolidated total income stood at 22,493 million. The Company reported a profit for the period of 564 million, contributing to a total comprehensive income of 373 million. Earnings per share (EPS) attributable to owners of the company stood at 3.57 based on basic and diluted calculations.The consolidated revenue from operations reached 22,294 million. The financial results show stability in key areas:
| Particulars | Quarter Ended June 30, 2026 (Unaudited) | Quarter Ended March 31, 2026 (Audited) | Quarter Ended June 30, 2025 (Unaudited) | Year Ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Total Revenue from Operations | 22,294 million | 22,900 million | 19,007 million | 82,796 million |
| Total Income | 22,493 million | 23,137 million | 19,127 million | 83,456 million |
| Profit for the Period | 564 million | 1,193 million | 1,025 million | 3,975 million |
Segment Revenue Details
The Group’s operations are segmented into several key areas, contributing to the total segment revenue of 22,555 million for the quarter ending June 30, 2026. The segments and their performance indicators include:| Segment | Revenue Contribution (million) | Profit Before Tax (million) |
|---|---|---|
| Radiopharma | 10,221 | 780 |
| Contract Development and Manufacturing Organisation - Sterile Injectables | 5,198 | 73 |
| Contract Research, Development and Manufacturing Organisation | 3,258 | 356 |
| Allergy Immunotherapy | 2,144 | 635 |
| Generics | 1,734 | (101) |
Standalone Financial Results
The standalone financial results for the quarter ended June 30, 2026, show Total Income of 672 million. The Company recorded a profit for the period from continuing operations amounting to 73 million. Total comprehensive income for the period was reported at 74 million.Standalone figures include:
| Particulars | Quarter Ended June 30, 2026 (Unaudited) |
|---|---|
| Total Income | 672 million |
| Total Expenses | 574 million |
| Profit for the Period from Continuing Operations | 73 million |
| Earnings Per Share (Basic/Diluted, continuing operations) | 0.46 |
JUBLPHARMA Stock Price Movement
Today, shares of Jubilant Pharmova Limited edged higher, settling at ₹962.7 after gaining 3.00% in post-market trading. The stock closed near its daily high amid robust trading activity, with a total volume of 357,574 shares exchanged today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.